JPWO2023081776A5 - - Google Patents

Info

Publication number
JPWO2023081776A5
JPWO2023081776A5 JP2024526594A JP2024526594A JPWO2023081776A5 JP WO2023081776 A5 JPWO2023081776 A5 JP WO2023081776A5 JP 2024526594 A JP2024526594 A JP 2024526594A JP 2024526594 A JP2024526594 A JP 2024526594A JP WO2023081776 A5 JPWO2023081776 A5 JP WO2023081776A5
Authority
JP
Japan
Prior art keywords
composition
mol
lipid
section
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542099A5 (https=
JP2024542099A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079244 external-priority patent/WO2023081776A1/en
Publication of JP2024542099A publication Critical patent/JP2024542099A/ja
Publication of JP2024542099A5 publication Critical patent/JP2024542099A5/ja
Publication of JPWO2023081776A5 publication Critical patent/JPWO2023081776A5/ja
Pending legal-status Critical Current

Links

JP2024526594A 2021-11-03 2022-11-03 核酸を含む脂質調合物、及び嚢胞性線維症の治療方法 Pending JP2024542099A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163275402P 2021-11-03 2021-11-03
US63/275,402 2021-11-03
PCT/US2022/079244 WO2023081776A1 (en) 2021-11-03 2022-11-03 Lipid formulations containing nucleic acids and methods of treatment for cystic fibrosis

Publications (3)

Publication Number Publication Date
JP2024542099A JP2024542099A (ja) 2024-11-13
JP2024542099A5 JP2024542099A5 (https=) 2025-11-12
JPWO2023081776A5 true JPWO2023081776A5 (https=) 2025-11-12

Family

ID=86242208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526594A Pending JP2024542099A (ja) 2021-11-03 2022-11-03 核酸を含む脂質調合物、及び嚢胞性線維症の治療方法

Country Status (6)

Country Link
US (1) US20230159449A1 (https=)
EP (1) EP4426266A4 (https=)
JP (1) JP2024542099A (https=)
AU (1) AU2022381750A1 (https=)
CA (1) CA3236675A1 (https=)
WO (1) WO2023081776A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12070509B2 (en) * 2020-05-01 2024-08-27 Arcturus Therapeutics, Inc. Nucleic acids and methods of treatment for cystic fibrosis
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
CN117653606B (zh) * 2023-11-14 2024-05-10 广东康百医药科技有限公司 一种间充质干细胞外泌体冻干保护剂及其应用
WO2025111297A1 (en) * 2023-11-21 2025-05-30 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2025166323A2 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. Crispr-related methods and compositions targeting lipoprotein (a) expression
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019013752A (es) * 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
ES3039647T3 (en) * 2017-05-31 2025-10-23 Arcturus Therapeutics Inc Synthesis and structure of high potency rna therapeutics
US12083224B2 (en) * 2018-03-30 2024-09-10 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery
KR20210091120A (ko) * 2018-08-29 2021-07-21 트랜슬레이트 바이오 인코포레이티드 Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정
WO2021183563A1 (en) * 2020-03-09 2021-09-16 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods

Similar Documents

Publication Publication Date Title
Maruyama et al. Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia
Voinea et al. Designing of ‘intelligent’liposomes for efficient delivery of drugs
Allen et al. Pharmacokinetics of long-circulating liposomes
Lian et al. Trends and developments in liposome drug delivery systems
ES2366978T3 (es) Nanocápsulas lipídicas furtivas, procedimientos para su preparación y utilización de las mismas como vehículo para principio(s) activo(s).
Khuller et al. Liposome technology for drug delivery against mycobacterial infections
JPWO2021222801A5 (https=)
AU714043B2 (en) Liposome-formulations for treatment of viral diseases
JP2005502653A (ja) 肺ガンの治療方法
CA2488385A1 (en) Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
Mizuguchi et al. Intratumor administration of fusogenic liposomes containing fragment A of diphtheria toxin suppresses tumor growth
US6468558B2 (en) Liposome-encapsulated poly ICLC
IL302065A (en) PAN-RAS mRNA CANCER VACCINES
Oku et al. Evaluation of drug targeting strategies and liposomal trafficking.
JPWO2023081776A5 (https=)
JPWO2022235935A5 (https=)
US20050260260A1 (en) Liposome compositions for the delivery of macromolecules
Allen et al. Sterically Stabilized (“Stealth”)
EP0731703B1 (en) Liposomal formulations containing vidarabine or its derivatives
WO2004078121A2 (en) Liposome composition for reduction of liposome-induced complement activation
Katre Liposome-based depot injection technologies: How versatile are they?
KR20220149400A (ko) 이황화 결합을 갖는 양이온성 지질을 사용하여 약물을 전달하기 위한 나노입자 조성물 및 그 제조방법
Bulbake et al. Liposomal drug delivery system and its clinically available products
Fielding et al. Liposomes in the treatment of infectious diseases
Katsumiiga et al. Membrane modification by negatively charged stearyl-polyoxyethylene derivatives for thermosensitive liposomes: reduced liposomal aggregation and avoidance of reticuloendothelial system uptake